Engineering Glycan Targeting Strategies to Enable Non-Invasive Transport Across the Blood Brain Barrier

• Introduce the cerebrovascular glycocalyx as a previously underexplored interface regulating blood–brain barrier transport and a novel target for therapeutic delivery
• Describe the design of mucin-binding protein shuttles that exploit glycosylated structures at the BBB to enable transcytosis of antibodies and biologics into the brain
• Evaluate how glycan-targeted delivery platforms compare with conventional systemic and invasive approaches in achieving efficient brain-wide biodistribution across multiple CNS cell types
• Discuss translational implications of leveraging endogenous BBB transport biology to improve delivery of large-molecule therapeutics for neurodegenerative disease and other CNS indications

Speakers:

Sophia Shi

Principal Investigator

Rowland Institute, Harvard University